STAT

Breathalyzers and brain caps: Researchers race to devise a roadside test for driving while high

A Breathalyzer for pot and a brain imaging cap are two of the technologies being tested for identifying drivers under the influence of marijuana.

The police sergeant’s voice was quiet but firm. She told the college student exactly what he was going to do, and then he did it.

“You’re going to take a series of nine heel-to-toe steps,” she said. “You’re going to look at your feet, you’re going to count your steps out loud, you’re going to keep your hands by your side, and you’re not going to stop once you start. … Then you’re going to come back.”

He put one foot carefully in front of the other, like a tightrope walker who’d made the mistake of looking down.

That sobriety test might have taken place on a windswept roadside, where Sgt. Deborah Batista had just pulled the student over for swerving across lanes. But they were going through the motions in the relative comfort of a Massachusetts General Hospital office building, where researchers were testing a brain imaging device to see whether it could identify people driving under the influence of pot.

As more and more states legalize , scientists and entrepreneurs are

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks